Abstract: One aspect of the present invention provides an anti-obesity agent, an anti-dementia agent, a deodorant, an anti-aging agent, an anti-glycation agent, an anti-type I allergy agent, a hypotensive agent, a flavor improving agent, a muscle enhancing agent, and a bone metabolism improving agent which contain a bagasse decomposition extract as an active ingredient.

Abstract: One aspect of the present invention provides an anti-obesity agent, an anti-dementia agent, a deodorant, an anti-aging agent, an anti-glycation agent, an anti-type I allergy agent, a hypotensive agent, a flavor improving agent, a muscle enhancing agent, and a bone metabolism improving agent which contain a bagasse decomposition extract as an active ingredient.

Abstract: According to an aspect of the present invention, there is provided an anti-I-type allergy agent including: p-coumaric acid as an active ingredient. In addition, according to another aspect of the present invention, there is provided an anti-dementia agent including: p-coumaric acid as an active ingredient.

Abstract: The present invention provides a Peyer's patch activator containing a polysaccharide obtained from sugar cane as an active ingredient, wherein the polysaccharide contains ?-glucan as a main component and has a peak molecular weight within a range of 720,000 to 1,080,000, with a proportion of glucose in all component sugars being 80% or more, and proportions of nonreducing terminal glucose and ?-1,6-linked glucose being 20 to 30% and 15 to 25%, respectively.

Abstract: PURPOSE: An object of the present invention is to provide a method for producing a sugar crystal-containing liquid with good reproducibility, wherein crystallization is enhanced, it is unnecessary to add seed crystals which may affect the number of grains and a size of the crystals, and graining conditions are stable. CONSTITUTION: The present invention is a method for producing a sugar crystal-containing liquid, wherein the method comprises steps of preparing a liquid supersaturated with sugar; and applying a shearing force to the liquid, characterized in that the step of applying the shearing force comprises exerting a pressure higher than atmospheric pressure on the liquid to make the liquid pass through a narrow space.

Abstract: PURPOSE: An object of the present invention is to provide a method for producing a sugar crystal-containing liquid with good reproducibility, wherein crystallization is enhanced, it is unnecessary to add seed crystals which may affect the number of grains and a size of the crystals, and graining conditions are stable. CONSTITUTION: The present invention is a method for producing a sugar crystal-containing liquid, wherein the method comprises steps of preparing a liquid supersaturated with sugar; and applying a shearing force to the liquid, characterized in that the step of applying the shearing force comprises exerting a pressure higher than atmospheric pressure on the liquid to make the liquid pass through a narrow space.

Abstract: The present invention provides a Peyer's patch activator containing a polysaccharide obtained from sugar cane as an active ingredient, wherein the polysaccharide contains ?-glucan as a main component and has a peak molecular weight within a range of 720,000 to 1,080,000, with a proportion of glucose in all component sugars being 80% or more, and proportions of nonreducing terminal glucose and ?-1,6-linked glucose being 20 to 30% and 15 to 25%, respectively.

Abstract: A method for reducing body fat accumulation is provided that includes: providing a reducer of body fat accumulation, wherein the reducer comprises isomaltulose; having an individual ingest the reducer; and having the individual consume a carbohydrate having an ?-1,6-glucosyl bond ratio of from 0% to less than 50% relative to the total bonds among constituent saccharides, wherein the reducer is ingested before or after or simultaneous with consuming the carbohydrate, and wherein the reducer reduces the individual's body fat accumulation caused by consuming the carbohydrate. The reducer of body fat accumulation includes isomaltulose (PALATINOSE™) as an active ingredient so that when the reducer is ingested and a carbohydrate having an ?-1,6-glucosyl bond ratio of from 0% to less than 50% relative to the total bonds among constituent saccharides is consumed, accumulation of body fat resulting from ingesting the carbohydrate is reduced.

Abstract: A method for reducing blood glucose level increase is provided that includes: providing a reducer of blood glucose level increase, wherein the reducer comprises isomaltulose; having an individual ingest the reducer; and having the individual consume a carbohydrate having an ?-1,6-glucosyl bond ratio of from 0% to less than 50% relative to the total bonds among constituent saccharides, wherein the reducer is ingested before or after or simultaneously with consuming the carbohydrate, and wherein the reducer reduces an increase in the individual's blood glucose level caused by consuming the carbohydrate. The reducer of blood glucose level increase includes isomaltulose (PALATINOSE™) as an active ingredient so that when the reducer is ingested and a carbohydrate having an ?-1,6-glucosyl bond ratio of from 0% to less than 50% relative to the total bonds among constituent saccharides is consumed, an increase in blood glucose level caused by ingesting the carbohydrate is reduced.

Abstract: The invention provides a stevia formulation comprising a stevia sweetener with a rebaudioside A content of 95% or greater, and 0.25 to 5.15 parts by weight of a sugarcane-derived extract (a), 0.06 to 2.50 parts by weight of a sugarcane-derived extract (b) and 0.002 to 12.5 parts by weight of ?-aminobutyric acid with respect to 100 parts by weight of the stevia sweetener.

Abstract: The invention provides a stevia formulation comprising a stevia sweetener with a rebaudioside A content of 95% or greater, and 0.25 to 5.15 parts by weight of a sugarcane-derived extract (a), 0.06 to 2.50 parts by weight of a sugarcane-derived extract (b) and 0.002 to 12.5 parts by weight of ?-aminobutyric acid with respect to 100 parts by weight of the stevia sweetener.

Abstract: A ketone body accumulation inhibitor that inhibits the accumulation of ketone bodies caused by exercising is provided in the present invention. The ketone body accumulation inhibitor contains isomaltulose as an active ingredient.

Abstract: Disclosed is a gene carrier composed of a hydrogen-bonding polymer having a polymer chain with hydrogen-bonding sites formed on the polymer chain, in which the polymer chain has a conformation similar to the conformation of a nucleic acid, and particularly, the polymer chain has helix parameters similar to the helix parameters of a nucleic acid of a helix structure. In a preferred embodiment, the hydrogen-bonding polymer is composed of ?-1,3-glucan such as schizophyllan. The carrier can be expected to be applied as a vector and a separator for nucleic acids because it is capable of interacting with a nucleic acid to form a complex with the nucleic acid and thus carrying the nucleic acid.

Abstract: Disclosed is a complex which comprises a carbon nanotube and a modified polysaccharide having a backbone chain with the side thereof being introduced with monosaccharide or oligosaccharide residues. The polysaccharide is preferably ?-1,3-glucan. The complex is prepared by admixing a solution of the modified polysaccharide dissolved in an aprotic polar solvent or a strong alkali solution with an aqueous dispersion of the carbon nanotube, and incubating the mixture.

Abstract: An object of the present invention is to provide a ketone body accumulation inhibitor which inhibits the accumulation of ketone bodies caused by exercising. The present invention provides a ketone body accumulation inhibitor containing isomaltulose as an active ingredient.

Abstract: A method for reducing body fat accumulation is provided that includes: providing a reducer of body fat accumulation, wherein the reducer comprises isomaltulose; having an individual ingest the reducer; and having the individual consume a carbohydrate having an ?-1,6-glucosyl bond ratio of from 0% to less than 50% relative to the total bonds among constituent saccharides, wherein the reducer is ingested before or after or simultaneous with consuming the carbohydrate, and wherein the reducer reduces the individual's body fat accumulation caused by consuming the carbohydrate. The reducer of body fat accumulation includes isomaltulose (PALATINOSE™) as an active ingredient so that when the reducer is ingested and a carbohydrate having an ?-1,6-glucosyl bond ratio of from 0% to less than 50% relative to the total bonds among constituent saccharides is consumed, accumulation of body fat resulting from ingesting the carbohydrate is reduced.

Abstract: A method for reducing blood glucose level increase is provided that includes: providing a reducer of blood glucose level increase, wherein the reducer comprises isomaltulose; having an individual ingest the reducer; and having the individual consume a carbohydrate having an ?-1,6-glucosyl bond ratio of from 0% to less than 50% relative to the total bonds among constituent saccharides, wherein the reducer is ingested before or after or simultaneously with consuming the carbohydrate, and wherein the reducer reduces an increase in the individual's blood glucose level caused by consuming the carbohydrate. The reducer of blood glucose level increase includes isomaltulose (PALATINOSE™) as an active ingredient so that when the reducer is ingested and a carbohydrate having an ?-1,6-glucosyl bond ratio of from 0% to less than 50% relative to the total bonds among constituent saccharides is consumed, an increase in blood glucose level caused by ingesting the carbohydrate is reduced.

Abstract: Disclosed is a new type of immunostimulating agent including an immunostimulating oligonucleotide complexed with a carrier which is safe and has a high transfection effect. The carrier complexed with the immunostimulating oligonucleotide to form the immunostimulating agent is a polysaccharide having ?-1,3-bonds (preferably ?-1,3-glucan such as schizophyllan). A preferred example of the immunostimulating oligonucleotide is one containing an unmethylated CpG motif. The polysaccharide for use is preferably modified with nucleic acid-binding functional group and/or cell membrane-affinitive functional group.

Abstract: Disclosed are gene carriers utilizing ?-1,3-glucan and methods of preparing the same. The ?-1,3-glucan has at least one 1,6-glucopyranoside branch and is chemically modified through periodate oxidation and reductive amination so as to impart nucleic acid-binding functional groups (for example, cationic functional groups) to at least some of the 1,6-glucopyranoside branches thereof. Triple helix ?-1,3-glucan is dissolved in a polar organic solvent to form single-stranded ?-1,3-glucan. By replacing, in the presence of a nucleic acid, the polar organic solvent for the solution containing the chemically modified single-stranded ?-1,3-glucan by water, a complex (gene carrier) is formed in which the nucleic acid is bound to double-stranded ?-1,3-glucan.

Abstract: Disclosed is a new type of immunostimulating agent including an immunostimulating oligonucleotide complexed with a carrier which is safe and has a high transfection effect. The carrier complexed with the immunostimulating oligonucleotide to form the immunostimulating agent is a polysaccharide having ?-1,3-bonds (preferably ?-1,3-glucan such as schizophyllan). A preferred example of the immunostimulating oligonucleotide is one containing an unmethylated CpG motif. The polysaccharide for use is preferably modified with nucleic acid-binding functional group and/or cell membrane-affinitive functional group.